Baxter, BD and B. Braun Melsungen AG are Dominating in the Asia-Pacific Bio Surgical Agents Market in 2020

Asia-Pacific Bio Surgical Agents Market is expected to grow with the CAGR of 7.7% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/asia-pacific-bio-surgical-agents-market

Asia-Pacific bio surgical agents market is a highly consolidated market which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in Asia-Pacific bio surgical agents market are introducing strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award and recognition into the market. This has helped the companies to maximize the sales with enhanced product portfolio. For instance, in October 2019, B. Braun Melsungen AG announced that they successfully collaborated with STANLEY Healthcare, thereby following integrating the Healthcare Enterprise Standards. The motive of this was in improving patient safety, asset utilization and staff efficiency. This improved their global reputation and attention from various customers which helped to enhance their company profit.

Baxter is the dominating player in Asia-Pacific bio surgical agents market. The other key players existing in the bio surgical agents market includes Integra LifeSciences Corporation, B. Braun Melsungen AG, Sanofi, Zimmer Biomet, NuVasive, Inc., Pfizer Inc., Wright Medical Group N.V., Anika Therapeutics, Inc., Equimedical, Adhezion Biomedical, CryoLife, Inc., AROA BIOSURGERY LIMITED, Exactech, Inc., Getinge AB, Smith & Nephew, Teleflex Incorporated, BD, Johnson & Johnson Services, Inc., Medtronic, Stryker and SAMYANG HOLDINGS CORPORATION among others.

Asia-Pacific Bio Surgical Agents Market

Baxter:

Baxter is headquartered in Illinois, U.S. and was incorporated in 1931. The company is engaged in offering products for domains such as acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals and surgical hemostat and sealant products. The company has multiple business segments including renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery, acute therapies and other in which advanced surgery is the market focused segment. The company has several products under categories such as patients and healthcare professionals in which healthcare professionals are the market focused category.

For instance,

  • In February 2020, Baxter has launched Peri-Strips Dry with secure grip technology for reliable staple line reinforcement in surgical procedures. This product launch has helped the company with sales and revenue growth.

The company has wide presence across North America, Europe, Middle East and Africa, Asia-Pacific and South America. The company also has various subsidiary companies such as Baxter Healthcare Pty Ltd (Australia), Baxter SA (Belgium), Baxter Corporation (Canada), Baxter Deutschland GmbH (Germany) and Baxter S.p.A. (Italy) among others.

BD:

BD is headquartered in New Jersey, U.S. and was incorporated in 1897. The company is engaged in the development, manufacturing and sale of wide range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The company has multiple business segments including medical, life sciences and interventional in which interventional is the market focused segment. The company has several products under categories including anesthesia delivery, biosciences, biosurgery, cervical cancer screening, diabetes care, drug delivery systems, gastrointestinal care, hazardous drug safety, hernia repair and fixation, home care, infection prevention, infusion therapy, interventional specialties, lab automation, medication and supply management, microbiology solutions, molecular diagnostics, patient monitoring and temperature management, prostate health, respiratory care, sharps disposal solutions, software solutions, specimen collection, surgical instruments, syringes and needles, urology and kidney health, vascular access, vascular surgery and wound care in which medication and supply management and lab automation are the market focused categories.

For instance,

  • In April 2021, BD has announced that it will present at the upcoming Bank of America Securities 2021 Virtual Healthcare Conference and the UBS Global Healthcare Virtual Conference. It is predicted that this participation anticipated the company's presence in the global market, leading to an upsurge for the sales growth.

The company has wide presence in North America, South America, Europe, Asia-Pacific and Middle East and Africa. The company also has various subsidiary companies such as Accuri Cytometers, Inc. (Delaware), Accuri Cytometers (Europe), Ltd. (U.K.), Atto Bioscience, Inc. (Delaware), B-D (U.K.) Ltd. (U.K.) among others.

B. Braun Melsungen AG:

B. Braun Melsungen AG is headquartered in Germany and was founded in 1839. The company is focused on providing the effective treatments along with the user friendly products and product systems that are cost effective and will provide the opportunities for the market. The company is engaged in providing wide range of products under categories such as abdominal surgery, diabetes care, infusion, nutrition therapy, ostomy care, wound management, cardio-thoracic surgery, interventional vascular therapy, orthopedic surgery, spine surgery, continence care & urology, extracorporeal blood treatment, sterile goods management, neurosurgery, infection prevention,  IV drugs, regional anesthesia, other products, wound management and wound closure in which wound closure is the market focused category.

For instance,

  • In March 2021, B. Braun Melsungen AG has announced that they have reconstituted their Supervisory Board with four new shareholders for their company. They resumed their work on the inaugural day session, thereby enhancing company’s product production and product portfolio. This is expected to increase their revenue for the future market.

The company is present in Africa, Asia-Pacific, Europe, South America and North America. The company also has various subsidiary companies such as Aesculap (Germany), Aesculap AG (Germany), B. Braun Avitum UK Ltd (U.K.), B. Braun GmbH (Germany), B. Braun of America, Inc. (America) among others.